Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 9/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 9/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559942 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL10166344 | 0.86 | CDK2 (0.47) | — | |
| SCHEMBL558793 | 0.86 | CDK2 (0.47) | — | |
| SCHEMBL558794 | 0.86 | CDK2 (0.47) | — | |
| SCHEMBL560212 | 0.84 | MAPK8 (0.44) | — | |
| SCHEMBL560213 | 0.84 | MAPK8 (0.44) | — | |
| SCHEMBL559140 | 0.84 | FAAH (0.50) | — | |
| SCHEMBL559336 | 0.84 | FAAH (0.50) | — | |
| SCHEMBL559337 | 0.84 | FAAH (0.50) | — | |
| SCHEMBL559139 | 0.84 | FAAH (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CHRNB2 3160/4885CHRNB4 3267/4885CHRNA3 3087/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CHRNB2 3160/4885CHRNB4 3267/4885CHRNA3 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.